The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Annual General Meeting

23 May 2023 16:30

Arix Bioscience PLC (ARIX) Result of Annual General Meeting 23-May-2023 / 16:30 GMT/BST


 

Arix Bioscience plc

 

Result of Annual General Meeting

 

LONDON, 23 May 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's .

 

No

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

TOTAL VOTES

% of ISC VOTED

VOTES WITHHELD

1

To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2022

68,931,411

100.00%

3,441

0.00%

 

68,934,852

 

 

53.28%

 

 

8,440

 

2

To approve the Directors' Remuneration Report

61,073,950

 

89.25%

 

 

7,358,207

 

 

10.75%

 

68,432,157

 

52.89%

 

 

511,135

 

3

To re-elect Peregrine Moncreiffe as a Director

68,099,019

 

98.79%

 

 

834,821

 

 

1.21%

 

68,933,840

 

53.28%

 

 

9,452

 

4

To re-elect Maureen O'Connell as a Director

68,894,053

 

99.94%

 

 

42,077

 

 

0.06%

 

68,936,130

 

53.28%

 

 

7,162

 

5

To re-elect Isaac Kohlberg as a Director

68,900,656

 

99.98%

 

 

17,184

 

 

0.02%

 

68,917,840

 

53.26%

 

 

25,452

 

6

To re-elect Robert Lyne as a Director

 

68,902,689

 

 

99.95%

 

 

31,595

 

 

0.05%

 

68,934,284

 

53.28%

 

 

9,008

 

7

To elect Dr. Debra Barker as a Director

68,907,528

 

99.95%

 

 

32,248

 

 

0.05%

 

68,939,776

 

53.28%

 

 

3,516

 

8

To elect Andrew Smith as a Director

 

68,921,195

 

 

99.98%

 

 

13,089

 

 

0.02%

 

68,934,284

 

53.28%

 

 

9,008

 

9

To appoint BDO LLP as auditors of the Company

68,929,881

 

99.99%

 

 

7,445

 

 

0.01%

 

68,937,326

 

53.28%

 

 

5,966

 

10

To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration

68,934,245

 

100.00%

 

 

2,013

 

 

0.00%

 

68,936,258

 

53.28%

 

 

7,034

 

11

To authorise the Directors to allot shares

65,989,256

 

95.72%

 

 

2,950,520

 

 

4.28%

 

68,939,776

 

53.28%

 

 

3,516

 

12

Authority to disapply statutory pre‐ emption rights

62,199,252

 

90.23%

 

 

6,734.680

 

 

9.77%

 

68,933,932

 

53.28%

 

 

9,360

 

13

Additional authority to disapply statutory pre‐ emption rights

62,202,105

 

90.23%

 

 

6,731,827

 

9.77%

68,933,932

 

53.28%

 

 

9,360

 

14

To authorise the Company to purchase its own shares

68,921,128

 

99.98%

 

 

17,177

 

 

0.02%

 

 

68,938,305

 

 

53.28%

 

 

4,987

 

15

Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice

68,145,351

 

98.85%

 

 

792,954

 

 

1.15%

 

68,938,305

 

53.28%

 

 

4,987

 

 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at .

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 25 April 2023, which is available on Arix investor relations .

[ENDS]

 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:RAG
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:245804
EQS News ID:1639935
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
3rd Dec 20187:00 amPRNAutolus announces update on AUTO4 and AUTO5 programmes
15th Nov 20187:00 amPRNPositive Phase 1 clinical trial results
12th Nov 20187:00 amPRNArix invests in $70m Harpoon Series C investment round
2nd Nov 201811:33 amPRNAutolus Therapeutics to Present New Data at the ASH
30th Oct 20182:11 pmPRNAura Biosciences reports positive Phase 1b/2 data
24th Oct 20187:00 amPRNLogicBio announces closing of initial public offering
19th Oct 20187:00 amPRNLogicBio prices Nasdaq IPO
10th Oct 20187:00 amPRNUpdate on LogicBio proposed IPO in the United States
1st Oct 20187:00 amPRNCo-leads $58 million Series A for VelosBio
26th Sep 20187:00 amPRNLogicBio files registration for proposed IPO in the US
18th Sep 20182:00 pmPRNUpdate on Iterum Therapeutics Phase 3 trials
12th Sep 20184:30 pmPRNAnnounces Board Changes
10th Sep 20184:24 pmPRNHolding(s) in Company
4th Sep 20187:00 amPRNChanges announced to executive team
17th Aug 20181:01 pmPRNHoldings in Company and Lock-in Agreement
10th Aug 20187:01 amPRNPositive clinical progression in Group Businesses
10th Aug 20187:00 amPRNArtios completes £65m Series B investment round
6th Aug 20187:00 amPRNArix Bioscience announces first VIPE investment
30th Jul 20187:00 amPRNInterim Results for the Six Months Ended 30 June 2018
25th Jul 20184:41 pmPRNNotice of Results
2nd Jul 20181:16 pmPRNTotal Voting Rights
26th Jun 20185:30 pmPRNAutolus annouces closing of IPO
22nd Jun 20187:07 amPRNAutolus Announces Pricing of Initial Public Offering
21st Jun 201810:22 amPRNIssue of Shares, Total Voting Rights & PDMR Notification
11th Jun 20184:23 pmPRNDirector/PDMR Shareholding
8th Jun 201811:36 amPRNUpdate on Autolus proposed NASDAQ IPO
31st May 20182:00 pmPRNLord John Hutton steps down from Board of Directors
30th May 20184:13 pmPRNIterum Therapeutics plc Closes Initial Public Offering
25th May 20187:19 amPRNIterum Therapeutics plc Prices Initial Public Offering
17th May 201812:29 pmRNSResult of AGM
17th May 20187:00 amRNSUpdate on Iterum proposed NASDAQ IPO
8th May 20187:00 amRNSAutolus Files for Proposed US IPO
2nd May 201810:10 amRNSArix notes Iterum?s proposed US IPO
23rd Apr 20187:00 amRNSAnnual Results 2017
16th Apr 20187:25 amRNSNotice of Annual Results
5th Apr 20187:00 amRNSArix to present at HC Wainwright on 10 April
4th Apr 20189:01 amRNSHolding(s) in Company
4th Apr 20189:00 amRNSTotal Voting Rights
26th Mar 20181:40 pmRNSHolding(s) in Company
26th Mar 201812:31 pmRNSArix notes positive Ph2b COPD data from Verona
23rd Mar 20189:00 amRNSHolding(s) in Company
22nd Mar 201811:51 amRNSHolding(s) in Company
21st Mar 201812:46 pmRNSHoldings in Company
21st Mar 201811:40 amRNSDirector/PDMR Shareholding
21st Mar 201811:39 amRNSHolding(s) in Company
16th Mar 201811:45 amRNSResults of General Meeting
16th Mar 20187:00 amRNSResults of Capital Raising
6th Mar 20187:00 amRNSArix notes Autolus's potential US IPO
28th Feb 201811:29 amRNSPublication of a Prospectus
28th Feb 20187:00 amRNSProposed Firm Placing, Placing and Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.